Bristol Myers Squibb Company (BMY) to Issue Quarterly Dividend of $0.63 on August 3rd

Bristol Myers Squibb Company (NYSE:BMY) declared a quarterly dividend on Wednesday, June 17th. Shareholders of record on Thursday, July 2nd will be given a dividend of 0.63 per share by the biopharmaceutical company on Monday, August 3rd. This represents a c) dividend on an annualized basis and a yield of 4.3%. The ex-dividend date is Thursday, July 2nd.

Bristol Myers Squibb has increased its dividend payment by an average of 0.0%annually over the last three years and has increased its dividend every year for the last 17 years. Bristol Myers Squibb has a payout ratio of 41.5% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Bristol Myers Squibb to earn $6.05 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 41.7%.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY opened at $58.46 on Tuesday. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $62.89. The company has a market cap of $119.37 billion, a PE ratio of 16.42, a P/E/G ratio of 0.16 and a beta of 0.24. The stock has a 50 day simple moving average of $57.05 and a 200-day simple moving average of $57.36. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the business earned $1.80 earnings per share. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts forecast that Bristol Myers Squibb will post 6.32 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday. HSBC increased their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Cantor Fitzgerald lifted their price target on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, April 8th. Finally, Guggenheim restated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $61.31.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.